SlideShare a Scribd company logo
1 of 65
Introduction
• In the past most drugs have been discovered either by
identifying the active ingredient from traditional
remedies or by serendipitous discovery.
• But now we know diseases are controlled at molecular
and physiological level.
• Also shape of an molecule at atomic level is well
understood.
• Information of Human Genome
History of Drug Discovery :
Pre 1919
• Herbal Drugs
• Serendiptious discoveries
1920s, 30s
• Vitamins
• Vaccines
1940s
• Antibiotic Era
• R&D Boost due to WW2
1950s
• New technology,
• Discovery of DNA
1960s
• Breakthrough in Etiology
1970s
• Rise of Biotechnology
• Use of IT
1980s
• Commercialization of
Drug Discovery
• Combinatorial Chemistry
1990s
• Robotics
• Automation
Registration:
• The Ministry of health & Family Welfare and the
Ministry of Chemicals & Fertilizers have major role in
regulation of IPM.
• NDA must be submitted to DCGI
• Phase III study reported to CDL, Kolkata
• Package inserted approved by DCI
• Marketing approval from FDA
• ~$800 M spent to bring a new drug to
market.
• $127 Billion spent on Pharma R&D in
2010
• Share of CROs in research operations
is 27%
• World CRO market is 16.3 B (Indian
share $500 M)
Market Scenerio:
18.8
R&D Share
Top CROs (By Revenue)
Contract Research Organizations Revenue
Quintiles $2.5 Billion
Pharmaceutical Product Development $1.8 Billion
Covance $1.4 Billion
Charles River Laboratories $1.2 Billion
Parexel $930 Million
Icon $887 Million
Kendle $590 Million
Pharmanet $470 Million
PRA International $410 Million
4G Pharmacovigilance $391 Million
Top CROs (India)
Contract Research Organizations Location
Actimus Biosciences Hyderabad
Advinus Therapeutics Bangalore
Aurigene Discovery technologies Bangalore
Chembiotek Kolkata
GVK Biosciences Hyderabad
Jubilant Organosys Bangalore
Ranbaxy Life Sciences Mumbai
Reliance Life Sciences Mumbai
Suven Life Sciences Hyderabad
Syngene Bangalore
Most valuable R&D Projects
Rank Product Company Phase Pharmacological class
Today's
NPV($mn)
1 Degludec Novo Nordisk Phase III Insulin 5,807
2 Tofacitinib Pfizer Phase III JAK-3 inhibitor 4,953
3 BG-12 Biogen Idec Phase III Fumarate 4,666
4 Incivek J & J Phase IV Hep C protease inhibitor 4,332
5 Relovair Theravance Phase III Corticosteroid 4,241
6 DR Cysteamine Undisclosed Phase III
Lysosomal transport
modulator
4,155
7 AMR 101 Undisclosed Phase III Omega-3 fatty acid 4,052
8 Eliquis Bristol Myers Squibb Phase IV Factor Xa inhibitor 3,836
9 Eliquis Pfizer Phase IV Factor Xa inhibitor 3,592
10 Bexssero Novartis Phase IV Meningococcal B vaccine 3,250
Top Companies by R&D Expense:
Sr. No. Company R & D spend($bn),2010
1 Novartis 7.9
2 Merck & Co 8.1
3 Roche 7.8
4 GlaxoSmithKline 5.7
5 Sanofi 5.8
6 Pfizer 9.1
7 Johnson & Johnson 4.5
8 Eli Lilly 4.7
9 AstraZeneca 4.2
10 Takeda 3.4
11 Bayer 2.3
12 Bristol-Myers Squibb 3.3
13 Boehringer Ingelheim 3.1
14 Amgen 2.8
15 Novo Nordisk 1.7
Drug Development Cost Break-up
R&D Function %
Discovery/Basic Research
Synthesis & Extraction 10.0
Biological Screening & testing 14.2
Preclinical Testing
Toxicology & Safety testing 4.5
Pharmaceutical Dosage Formulation 7.3
Clinical Trials
Phase I, II, III 29.1
Phase IV 11.7
Manufacturing & QC 8.3
IND & NDA 4.1
Bioavailability 1.8
Others 9.0
Total 100.0
10,000
COMPOUNDS
250
COMPOUNDS 5 COMPOUNDS
1 FDA
APPROVED
DRUG
~6.5 YEARS ~7 YEARS ~1.5 YEARS
DRUG
DISCOVERY
PRECLINICAL
CLINICAL TRIALS FDA
REVIEW
Drug Discovery &
Development-Timeline
Drug Discovery
• Drugs Discovery methods:
– Random Screening
– Molecular Manipulation
– Molecular Designing
– Drug Metabolites
– Serendipity
Target
Selection
• Cellular and
Genetic
Targets
• Genomics
• Proteomics
• Bioinformatics
Lead
Discovery
• Synthesis and
Isolation
• Combinatorial
Chemistry
• Assay
development
• High-
Throughput
Screening
Medicinal
Chemistry
• Library
Development
• SAR Studies
• In Silico
Screening
• Chemical
Synthesis
In Vitro
Studies
• Drug Affinity
and
Selectivity
• Cell Disease
Models
• MOA
• Lead
Candidate
Refinement
In Vivo
Studies
• Animal
models of
Disease States
• Behavioural
Studies
• Functional
Imaging
• Ex-Vivo
Studies
Clinical
Trials and
Therapeutics
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Target Selection
• Target selection in drug discovery is defined as the
decision to focus on finding an agent with a particular
biological action that is anticipated to have therapeutic
utility — is influenced by a complex balance of scientific,
medical and strategic considerations.
• Target identification: to identify molecular targets that
are involved in disease progression.
• Target validation: to prove that manipulating the
molecular target can provide therapeutic benefit for
patients.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Target Selection
Biochemical Classes of Drug Targets
 G-protein coupled receptors - 45%
 enzymes - 28%
 hormones and factors - 11%
 ion channels - 5%
 nuclear receptors - 2%
Techniques for Target Identification
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Cellular & Genetic Targets:
Involves the identification of the function of a potential therapeutic drug
target and its role in the disease process.
For small-molecule drugs, this step in the process involves identification
of the target receptors or enzymes whereas for some biologic
approaches the focus is at the gene or transcription level.
Drugs usually act on either cellular or genetic chemicals in the body,
known as targets, which are believed to be associated with disease.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Cellular & Genetic Targets:
Scientists use a variety of techniques to identify and
isolate individual targets to learn more about their
functions and how they influence disease.
Compounds are then identified that have various
interactions with the drug targets that might be
helpful in treatment of a specific disease.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Genomics:
The study of genes and their function. Genomics aims to
understand the structure of the genome, including the mapping
genes and sequencing the DNA.
Seeks to exploit the findings from the sequencing of the human
and other genomes to find new drug targets.
Human Genome consists of a sequence of around 3 billion
nucleotides (the A C G T bases) which in turn probably encode
35,000 – 50,000 genes.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Genomics:
Drew’s estimates that the number of genes implicated in disease,
both those due to defects in single genes and those arising from
combinations of genes, is about 1,000
Based on 5 or 10 linked proteins per gene, he proposes that the
number of potential drug targets may lie between 5,000 and
10,000.
Single Nucleotide Polymorphism (SNP) libraries: are used to
compare the genomes from both healthy and sick people and to
identify where their genomes vary.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Proteomics:
It is the study of the proteome, the complete set of proteins
produced by a species, using the technologies of large – scale protein
separation and identification.
It is becoming increasingly evident that the complexity of biological
systems lies at the level of the proteins, and that genomics alone will
not suffice to understand these systems.
It is also at the protein level that disease processes become manifest,
and at which most (91%) drugs act.
Therefore, the analysis of proteins (including protein-protein, protein-
nucleic acid, and protein ligand interactions) will be utmost importance
to target discovery.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Proteomics:
Proteomics is the systematic high-throughput separation
and characterization of proteins within biological systems.
Target identification with proteomics is performed by
comparing the protein expression levels in normal and
diseased tissues.
2D PAGE is used to separate the proteins, which are
subsequently identified and fully characterized with LC-
MS/MS.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Bioinformatics:
Bioinformatics is a branch of molecular biology that involves extensive analysis of
biological data using computers, for the purpose of enhancing biological research.
It plays a key role in various stages of the drug discovery process including
 target identification
 computer screening of chemical compounds and
 pharmacogenomics
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Cellular &
Genetic Targets
Genomics
Proteomics
Bioinformatics
Bioinformatics:
Bioinformatics methods are used to transform the raw sequence
into meaningful information (eg. genes and their encoded
proteins) and to compare whole genomes (disease vs. not).
Can compare the entire genome of pathogenic and non-
pathogenic strains of a microbe and identify genes/proteins
associated with pathogenism
Using gene expression micro arrays and gene chip technologies, a
single device can be used to evaluate and compare the
expression of up to 20000 genes of healthy and diseased
individuals at once
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
Lead Discovery:
• Identification of small molecule modulators of
protein function
• The process of transforming these into high-
content lead series.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
Synthesis and Isolation:
• Separation of mixture
• Separation of impurities
• In vitro chemical synthesis
• Biosynthetic intermediate
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
Combinatorial Chemistry:
Rapid synthesis of or computer simulation of
large no. of different but structurally related
molecules
• Search new leads
• Optimization of target affinity & selectivity.
• ADME properties
• Reduce toxicity and eliminate side effects
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
Assay Development
• Used for measuring the activity of a drug.
• Discriminate between compounds.
• Evaluate:
• Expressed protein targets.
• Enzyme/ substrate interactions.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
High throughput screening:
• Screening of drug target against selection of
chemicals.
• Identification of highly target specific
compounds.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Synthesis and
Isolation
Combinatorial
Chemistry
Assay
Development
High
Throughput
Screening
High throughput screening:
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
Medicinal Chemistry:
• It’s a discipline at the intersection of synthetic
organic chemistry and parmacology.
• Focuses on small organic molecules (and not
on biologics and inorganic compounds)
• Used in
• Drug discovery (hits)
• Lead optimization (hit to lead)
• Process chemistry and development
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
Library Development:
• Collection of stored chemicals along with
associated database.
• Assists in High Throughput Screening
• Helps in screening of drug target (hit)
• Based on organic chemistry
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
SAR Studies:
• Helps identify pharmacophore
• The pharmacophore is the precise section of
the molecule that is responsible for biological
activity
• Enables to prepare more active compound
• Allow elimination of excessive functionality
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
SAR Studies:
Morphine Molecule
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
In silico screening:
• Computer simulated screening of chemicals
• Helps in finding structures that are most likely
to bind to drug target.
• Filter enormous Chemical space
• Economic than HTS
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Library
Development
SAR Studies
In Silico
Screening
Chemical
Synthesis
Chemical Synthesis:
• Involve production of lead compound in
suitable quantity and quality to allow large
scale animal and eventual, extensive human
clinical trials
• Optimization of chemical route for bulk
industrial production.
• Suitable drug formulation
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Drug Affinity
and Selectivity
Cell Disease
Models
MOA
Lead Candidate
Refinement
In Vitro Studies:
• (In glass) studies using component of organism i.e. test tube
experiments
• Examples-
• Cells derived from multicellular organisms
• Subcellular components (Ribosomes, mitochondria)
• Cellular/ subcellular extracts (wheat germ, reticulocyte
extract)
• Purified molecules (DNA,RNA)
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Drug Affinity
and Selectivity
Cell Disease
Models
MOA
Lead Candidate
Refinement
In Vitro Studies:
Advantages:
• Studies can be completed in short period of time.
• Reduces risk in post clinical trials
• permits an enormous level of simplification of the system
• investigator can focus on a small number of components
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Drug Affinity
and Selectivity
Cell Disease
Models
MOA
Lead Candidate
Refinement
Drug affinity and selectivity
• Drug affinity is the ability of drug to bind to its biological
target (receptor, enzyme, transport system, etc.)
• Selectivity- Drug should bind to specific receptor site on the
cell (eg. Aspirin)
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Drug Affinity
and Selectivity
Cell Disease
Models
MOA
Lead Candidate
Refinement
• Isogenic human disease models- are a family of cells that are
selected or engineered to accurately model the genetics of a specific
patient population, in vitro
• Stem cell disease models-Adult or embryonic stem cells carrying
or induced to carry defective genes can be investigated in vitro to
understand latent molecular mechanisms and disease characteristics
Cell disease models
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Drug Affinity
and Selectivity
Cell Disease
Models
MOA
Lead Candidate
Refinement
• Optimizing chemical hits for clinical trial is commonly referred
to as lead optimization
• The refinement in structure is necessary in order to improve
• Potency
• Oral Availability
• Selectivity
• pharmacokinetic properties
• safety (ADME properties)
Lead Candidate refinement
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Animal models of
Disease States
Behavioural
Studies
Functional
Imaging
Ex-Vivo Studies
In vivo studies
• Its experimentation using a whole, living
organism.
• Gives information about,
• Metabolic profile
• Toxicology
• Drug interaction
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Animal models of
Disease States
Behavioural
Studies
Functional
Imaging
Ex-Vivo Studies
Animal models of disease states
• Test conditions involving induced disease or
injury similar to human conditions.
• Must be equivalent in mechanism of cause.
• Can predict human toxicity in 71% of the
cases.
• Eg. SCID mice-HIV
NOD mice- Diabetes
Danio rerio- Gene function
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Animal models of
Disease States
Behavioural
Studies
Functional
Imaging
Ex-Vivo Studies
Behavioural Studies
• Tools to investigate behavioural results of drugs.
• Used to observe depression and mental disorders.
• However self esteem and suicidality are hard to induce.
• Example:
• Despair based- Forced swimming/ Tail suspension
• Reward based
• Anxiety Based
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Animal models of
Disease States
Behavioural
Studies
Functional
Imaging
Ex-Vivo Studies
Functional Imaging:
• Method of detecting or measuring changes in
metabolism, blood flow, regional chemical
composition, and absorption.
• Tracers or probes used.
• Modalities Used-
• MRI
• CT-Scan
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Animal models of
Disease States
Behavioural
Studies
Functional
Imaging
Ex-Vivo Studies
Ex-Vivo Studies:
• Experimentation on tissue in an artificial
environment outside the organism with the
minimum alteration of natural conditions.
• Counters ethical issues.
• Examples:
• Measurement of tissue properties
• Realistic models for surgery
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Clinical trials:
• Set of procedures in medical research and
drug development to study the safety and
efficacy of new drug.
• Essential to get marketing approval from
regulatory authorities.
• May require upto 7 years.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase 0:
• Recent designation, also known as human micro-dosing
studies.
• First in human trials, conducted to study exploratory
investigational new drug.
• Designed to to speed up the development of promising
drugs.
• Concerned with-
• Preliminary data on the drug’s pharmacodynamics
and pharmacokinetics
• Efficacy of pre-clinical studies.
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase I:
• Clinical Pharmacologic Evaluation
• First stage of testing in human subjects.
• 20-50 Healthy Volunteers
• Concerned With:
– Human Toxicity.
– Tolerated Dosage Range
– Pharma-cology/dynamics
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase I:
Types of Phase-I Trials
• SAD (Single Ascending Dose)
• MAD (Multiple Ascending Dose)
• Food effect
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase II:
• Controlled Clinical Evaluation.
• 50-300 Patients
• Controlled Single Blind Technique
• Concerned With:
– Safety
– Efficacy
– Drug Toxicity
– Drug Interaction
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase III:
• Extended Clinical Trials.
• Most expensive & time consuming.
• 250-1000 Patients.
• Controlled Double Blind Technique.
• Concerned With:
– Safety, Efficacy
– Comparison with other Drugs
– Package Insert
Target Selection Lead
Discovery
Medicinal
Chemistry
In Vitro
Studies
In Vivo
Studies
Clinical
Trials
Phase-I
Phase-II
Phase-III
Phase-IV
Phase IV:
• Post Marketing Surveillance.
• Designed to detect any rare or long-term
adverse effects.
• Adverse Drug Reaction Monitoring.
• Pharmacovigilance.
10,000
COMPOUNDS
250
COMPOUNDS 5 COMPOUNDS
1 FDA
APPROVED
DRUG
~6.5 YEARS ~7 YEARS ~1.5 YEARS
DRUG
DISCOVERY
PRECLINICAL
CLINICAL TRIALS FDA
REVIEW
Drug Discovery &
Development-Timeline
Gene Therapy
• Technique for correcting
defective genes.
• It is the process of inserting
genes into cells to treat
diseases.
• Gene therapy is used to
correct a deficient phenotype.
Gene Therapy-Approaches
Germline Gene Therapy
 Sperm or eggs, are modified by the introduction of functional genes, which
are integrated into their genomes.
 Change would be heritable and would be passed on to later generations.
Somatic Gene Therapy
 The therapeutic genes are transferred
Into the somatic cells of a patient.
 Change will not be inherited by the
patient's offspring or later generations.
Gene Therapy- Types
Ex Vivo Gene Therapy
 Transfer of therapeutic genes in cultured cells which are then reintroduced
into patient.
Eg: Therapy for ADA Deficiency
In Vivo Gene Therapy
 The direct delivery of genes into the cells of a particular tissue is referred
to as in vivo gene therapy.
Eg: Therapy for Cystic fibrosis
Gene Therapy- Vectors
• Viruses
Retroviruses
Adenoviruses
Adeno-associated viruses
Herpes Simplex viruses
• Pure DNA Constructs
• Lipoplexes
• DNA Molecular Conjugates
• Human Artificial Chromosome
Gene Therapy- Limitations
• Short lived nature of gene therapy
• Immune response
• Problems with viral vectors
• Multigene disorders
Recent Developments
• Nanotechnology + gene therapy yielded treatment to
torpedo cancer
• Results of world's first gene therapy for inherited
blindness show sight improvement
• New Method of Gene Therapy Alters Immune Cells for
Treatment of Advanced Melanoma
• Dual Gene Therapy Suppresses Lung Cancer in
Preclinical Test
Orphan Drugs:
• An orphan drug is a pharmaceutical agent that has been
developed specifically to treat a rare medical condition,
the condition itself being referred to as an orphan disease.
• National Organization for Rare
Disorders
• European Organization for Rare
Diseases
Advantages:
• Tax incentives.
• Enhanced patent protection and marketing rights.
• Clinical research financial subsidization.
• Rise in research and developmen.
• Crown Corporation.
Orphan Drugs Act:
• 4th January 1983
• 6000 Orphan Diseases
• Unprofitable Drug Development
• Affecting < 2,00,000 Persons
• Orphan Drug Status to 1,090
Drugs
• 1985 Amendment- Marketing
Exclusivity
Tourette Syndrome
An Orphan Disease
FDA Orphan Drug Approvals:
43
19
17
19
2
% Share
Big Pharma
Small Biopharma
Established
Biopharma
Small & Medium
Pharma
Rare Diseases & Orphan Drugs:
Sr. Disease Cause Orphan Drug
1. Gaucher’s Disease Glucocerbrosidase Enzyme Miglustat
2. Fabry’s Disease Galactosidase Enyme Galsidase β
3. Mucopolysaccharidosis Lysosomal Enzyme Laronidase
4. Tourette’s Syndrome Motor Tics Lamotrizine
5. Crohn’s Syndrome Unknown Infliximab
6. Wilson Disease Copper Deposition Trientine
7. SCID Adenosine Deaminase Enzyme Pegadimase
Drug discovery and development

More Related Content

What's hot

Drug development process
Drug development processDrug development process
Drug development processnasim arshadi
 
Drug development process
Drug development processDrug development process
Drug development processPawanDhamala1
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studiesAzeemsales
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentSharafudheenKa4
 
Drug development process.
Drug development process.Drug development process.
Drug development process.Akhil Joseph
 
Target identification in drug discovery
Target identification in drug discoveryTarget identification in drug discovery
Target identification in drug discoverySwati Kumari
 
Drug discovery
Drug discoveryDrug discovery
Drug discoverySaba Ahmed
 
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxPRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxDharaMehta45
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug ApplicationSuhas Reddy C
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Sagar Savale
 
Drug discovery & development
Drug discovery & developmentDrug discovery & development
Drug discovery & developmentShubham Patil
 
Target identification and validation
Target identification and validationTarget identification and validation
Target identification and validationAshishVerma571
 
Drug discovery presentation
Drug discovery presentationDrug discovery presentation
Drug discovery presentationSneha Mathew
 

What's hot (20)

Drug development process
Drug development processDrug development process
Drug development process
 
Drug discovery hit to lead
Drug discovery hit to leadDrug discovery hit to lead
Drug discovery hit to lead
 
Drug development process
Drug development processDrug development process
Drug development process
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studies
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Drug development process.
Drug development process.Drug development process.
Drug development process.
 
Target identification in drug discovery
Target identification in drug discoveryTarget identification in drug discovery
Target identification in drug discovery
 
Drug discovery
Drug discoveryDrug discovery
Drug discovery
 
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxPRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)
 
Drug discovery & development
Drug discovery & developmentDrug discovery & development
Drug discovery & development
 
Target identification and validation
Target identification and validationTarget identification and validation
Target identification and validation
 
Principles of drug discovery
Principles of drug discoveryPrinciples of drug discovery
Principles of drug discovery
 
Phases of clinical trials
Phases of clinical trialsPhases of clinical trials
Phases of clinical trials
 
QSAR
QSARQSAR
QSAR
 
Drug discovery presentation
Drug discovery presentationDrug discovery presentation
Drug discovery presentation
 
New drug development
New drug developmentNew drug development
New drug development
 
Drug discovery
Drug discoveryDrug discovery
Drug discovery
 
Pre Clinical Studies
Pre Clinical StudiesPre Clinical Studies
Pre Clinical Studies
 

Viewers also liked

Drug development and clinical trial phases
Drug development and clinical trial phasesDrug development and clinical trial phases
Drug development and clinical trial phasesSunil Boreddy Rx
 
Drug Development Life Cycle
Drug Development Life CycleDrug Development Life Cycle
Drug Development Life CycleRajendra Sadare
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug applicationGaurav Kr
 
Drug Discovery & Development Overview
Drug Discovery & Development OverviewDrug Discovery & Development Overview
Drug Discovery & Development OverviewMikeSumner
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesSlideTeam.net
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueRobert Sturm
 
Computer aided drug design
Computer aided drug designComputer aided drug design
Computer aided drug designN K
 
Drug discovery process style 3 powerpoint presentation templates
Drug discovery process style 3 powerpoint presentation templatesDrug discovery process style 3 powerpoint presentation templates
Drug discovery process style 3 powerpoint presentation templatesSlideTeam.net
 
Systems Pharmacology 1: Drug re-positioning prediction
Systems Pharmacology 1: Drug re-positioning predictionSystems Pharmacology 1: Drug re-positioning prediction
Systems Pharmacology 1: Drug re-positioning predictionAli Kishk
 
Drug discovery process powerpoint presentation slides ppt templates
Drug discovery process powerpoint presentation slides ppt templatesDrug discovery process powerpoint presentation slides ppt templates
Drug discovery process powerpoint presentation slides ppt templatesSlideTeam.net
 
Lead drug discovery
Lead drug discoveryLead drug discovery
Lead drug discoverysanchitbaba
 
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationIn Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationOSUCCC - James
 
Repositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesRepositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesYannick Pouliot
 
Drug Repositioning Workshop
Drug Repositioning WorkshopDrug Repositioning Workshop
Drug Repositioning WorkshopGenna Gerla
 
Research and Development
Research and DevelopmentResearch and Development
Research and DevelopmentShameem Ali
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 

Viewers also liked (20)

Drug development and clinical trial phases
Drug development and clinical trial phasesDrug development and clinical trial phases
Drug development and clinical trial phases
 
Drug Development Life Cycle
Drug Development Life CycleDrug Development Life Cycle
Drug Development Life Cycle
 
Investigational new drug application
Investigational new drug applicationInvestigational new drug application
Investigational new drug application
 
Drug Discovery & Development Overview
Drug Discovery & Development OverviewDrug Discovery & Development Overview
Drug Discovery & Development Overview
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templates
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and Revenue
 
‫Thyroid gland disorders
‫Thyroid gland disorders‫Thyroid gland disorders
‫Thyroid gland disorders
 
Drug Design:Discovery, Development and Delivery
Drug Design:Discovery, Development and DeliveryDrug Design:Discovery, Development and Delivery
Drug Design:Discovery, Development and Delivery
 
Parsimony methods
Parsimony methodsParsimony methods
Parsimony methods
 
Computer aided drug design
Computer aided drug designComputer aided drug design
Computer aided drug design
 
Drug discovery process style 3 powerpoint presentation templates
Drug discovery process style 3 powerpoint presentation templatesDrug discovery process style 3 powerpoint presentation templates
Drug discovery process style 3 powerpoint presentation templates
 
Systems Pharmacology 1: Drug re-positioning prediction
Systems Pharmacology 1: Drug re-positioning predictionSystems Pharmacology 1: Drug re-positioning prediction
Systems Pharmacology 1: Drug re-positioning prediction
 
Drug discovery process powerpoint presentation slides ppt templates
Drug discovery process powerpoint presentation slides ppt templatesDrug discovery process powerpoint presentation slides ppt templates
Drug discovery process powerpoint presentation slides ppt templates
 
Lead drug discovery
Lead drug discoveryLead drug discovery
Lead drug discovery
 
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead GenerationIn Vitro ADMET Considerations for Drug Discovery and Lead Generation
In Vitro ADMET Considerations for Drug Discovery and Lead Generation
 
Repositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational ApproachesRepositioning Old Drugs For New Indications Using Computational Approaches
Repositioning Old Drugs For New Indications Using Computational Approaches
 
[4] drug discovery-lect-1
[4] drug discovery-lect-1[4] drug discovery-lect-1
[4] drug discovery-lect-1
 
Drug Repositioning Workshop
Drug Repositioning WorkshopDrug Repositioning Workshop
Drug Repositioning Workshop
 
Research and Development
Research and DevelopmentResearch and Development
Research and Development
 
New drug application
New drug applicationNew drug application
New drug application
 

Similar to Drug discovery and development

Drugdiscoveryanddevelopment by khadga raj
Drugdiscoveryanddevelopment by khadga rajDrugdiscoveryanddevelopment by khadga raj
Drugdiscoveryanddevelopment by khadga rajKhadga Raj
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery processThanh Truong
 
drug discovery
drug discoverydrug discovery
drug discoverymarymelna1
 
Genomics and proteomics in drug discovery and development
Genomics and proteomics in drug discovery and developmentGenomics and proteomics in drug discovery and development
Genomics and proteomics in drug discovery and developmentSuchittaU
 
Role of bioinformatics in drug designing
Role of bioinformatics in drug designingRole of bioinformatics in drug designing
Role of bioinformatics in drug designingW Roseybala Devi
 
Target discovery and validation
Target discovery and validation Target discovery and validation
Target discovery and validation ANAND SAGAR TIWARI
 
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxPRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxDharaMehta45
 
Bioinformatics ( Dharal Mistry ) M.Pharm
Bioinformatics ( Dharal Mistry ) M.PharmBioinformatics ( Dharal Mistry ) M.Pharm
Bioinformatics ( Dharal Mistry ) M.Pharm1925DharalMistry
 
1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.Audumbar Mali
 
Bioinformatics in drug discovery
Bioinformatics in drug discoveryBioinformatics in drug discovery
Bioinformatics in drug discoveryKAUSHAL SAHU
 
Research Avenues in Drug discovery of natural products
Research Avenues in Drug discovery of natural productsResearch Avenues in Drug discovery of natural products
Research Avenues in Drug discovery of natural productsDevakumar Jain
 
APPLICATION OF METABOLOMICS.pdf
APPLICATION OF METABOLOMICS.pdfAPPLICATION OF METABOLOMICS.pdf
APPLICATION OF METABOLOMICS.pdfAmity
 
Application of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drugApplication of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drugmanojsiddartha bolthajira
 

Similar to Drug discovery and development (20)

Drugdiscoveryanddevelopment by khadga raj
Drugdiscoveryanddevelopment by khadga rajDrugdiscoveryanddevelopment by khadga raj
Drugdiscoveryanddevelopment by khadga raj
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery process
 
drug discovery
drug discoverydrug discovery
drug discovery
 
Genomics and proteomics in drug discovery and development
Genomics and proteomics in drug discovery and developmentGenomics and proteomics in drug discovery and development
Genomics and proteomics in drug discovery and development
 
Role of bioinformatics in drug designing
Role of bioinformatics in drug designingRole of bioinformatics in drug designing
Role of bioinformatics in drug designing
 
DRUG discovery
DRUG discoveryDRUG discovery
DRUG discovery
 
Biomarkers & Clinical Research
Biomarkers & Clinical ResearchBiomarkers & Clinical Research
Biomarkers & Clinical Research
 
Drug discovery
Drug discoveryDrug discovery
Drug discovery
 
Target discovery and validation
Target discovery and validation Target discovery and validation
Target discovery and validation
 
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxPRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptx
 
Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.
 
QSRR
QSRRQSRR
QSRR
 
Bioinformatics ( Dharal Mistry ) M.Pharm
Bioinformatics ( Dharal Mistry ) M.PharmBioinformatics ( Dharal Mistry ) M.Pharm
Bioinformatics ( Dharal Mistry ) M.Pharm
 
1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.
 
Bioinformatics in drug discovery
Bioinformatics in drug discoveryBioinformatics in drug discovery
Bioinformatics in drug discovery
 
Research Avenues in Drug discovery of natural products
Research Avenues in Drug discovery of natural productsResearch Avenues in Drug discovery of natural products
Research Avenues in Drug discovery of natural products
 
APPLICATION OF METABOLOMICS.pdf
APPLICATION OF METABOLOMICS.pdfAPPLICATION OF METABOLOMICS.pdf
APPLICATION OF METABOLOMICS.pdf
 
Application of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drugApplication of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drug
 
Cancer biomarker
Cancer biomarkerCancer biomarker
Cancer biomarker
 

Recently uploaded

systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 

Recently uploaded (20)

systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 

Drug discovery and development

  • 1.
  • 2. Introduction • In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. • But now we know diseases are controlled at molecular and physiological level. • Also shape of an molecule at atomic level is well understood. • Information of Human Genome
  • 3. History of Drug Discovery : Pre 1919 • Herbal Drugs • Serendiptious discoveries 1920s, 30s • Vitamins • Vaccines 1940s • Antibiotic Era • R&D Boost due to WW2 1950s • New technology, • Discovery of DNA 1960s • Breakthrough in Etiology 1970s • Rise of Biotechnology • Use of IT 1980s • Commercialization of Drug Discovery • Combinatorial Chemistry 1990s • Robotics • Automation
  • 4. Registration: • The Ministry of health & Family Welfare and the Ministry of Chemicals & Fertilizers have major role in regulation of IPM. • NDA must be submitted to DCGI • Phase III study reported to CDL, Kolkata • Package inserted approved by DCI • Marketing approval from FDA
  • 5. • ~$800 M spent to bring a new drug to market. • $127 Billion spent on Pharma R&D in 2010 • Share of CROs in research operations is 27% • World CRO market is 16.3 B (Indian share $500 M) Market Scenerio: 18.8 R&D Share
  • 6. Top CROs (By Revenue) Contract Research Organizations Revenue Quintiles $2.5 Billion Pharmaceutical Product Development $1.8 Billion Covance $1.4 Billion Charles River Laboratories $1.2 Billion Parexel $930 Million Icon $887 Million Kendle $590 Million Pharmanet $470 Million PRA International $410 Million 4G Pharmacovigilance $391 Million
  • 7. Top CROs (India) Contract Research Organizations Location Actimus Biosciences Hyderabad Advinus Therapeutics Bangalore Aurigene Discovery technologies Bangalore Chembiotek Kolkata GVK Biosciences Hyderabad Jubilant Organosys Bangalore Ranbaxy Life Sciences Mumbai Reliance Life Sciences Mumbai Suven Life Sciences Hyderabad Syngene Bangalore
  • 8. Most valuable R&D Projects Rank Product Company Phase Pharmacological class Today's NPV($mn) 1 Degludec Novo Nordisk Phase III Insulin 5,807 2 Tofacitinib Pfizer Phase III JAK-3 inhibitor 4,953 3 BG-12 Biogen Idec Phase III Fumarate 4,666 4 Incivek J & J Phase IV Hep C protease inhibitor 4,332 5 Relovair Theravance Phase III Corticosteroid 4,241 6 DR Cysteamine Undisclosed Phase III Lysosomal transport modulator 4,155 7 AMR 101 Undisclosed Phase III Omega-3 fatty acid 4,052 8 Eliquis Bristol Myers Squibb Phase IV Factor Xa inhibitor 3,836 9 Eliquis Pfizer Phase IV Factor Xa inhibitor 3,592 10 Bexssero Novartis Phase IV Meningococcal B vaccine 3,250
  • 9. Top Companies by R&D Expense: Sr. No. Company R & D spend($bn),2010 1 Novartis 7.9 2 Merck & Co 8.1 3 Roche 7.8 4 GlaxoSmithKline 5.7 5 Sanofi 5.8 6 Pfizer 9.1 7 Johnson & Johnson 4.5 8 Eli Lilly 4.7 9 AstraZeneca 4.2 10 Takeda 3.4 11 Bayer 2.3 12 Bristol-Myers Squibb 3.3 13 Boehringer Ingelheim 3.1 14 Amgen 2.8 15 Novo Nordisk 1.7
  • 10. Drug Development Cost Break-up R&D Function % Discovery/Basic Research Synthesis & Extraction 10.0 Biological Screening & testing 14.2 Preclinical Testing Toxicology & Safety testing 4.5 Pharmaceutical Dosage Formulation 7.3 Clinical Trials Phase I, II, III 29.1 Phase IV 11.7 Manufacturing & QC 8.3 IND & NDA 4.1 Bioavailability 1.8 Others 9.0 Total 100.0
  • 11. 10,000 COMPOUNDS 250 COMPOUNDS 5 COMPOUNDS 1 FDA APPROVED DRUG ~6.5 YEARS ~7 YEARS ~1.5 YEARS DRUG DISCOVERY PRECLINICAL CLINICAL TRIALS FDA REVIEW Drug Discovery & Development-Timeline
  • 12. Drug Discovery • Drugs Discovery methods: – Random Screening – Molecular Manipulation – Molecular Designing – Drug Metabolites – Serendipity
  • 13. Target Selection • Cellular and Genetic Targets • Genomics • Proteomics • Bioinformatics Lead Discovery • Synthesis and Isolation • Combinatorial Chemistry • Assay development • High- Throughput Screening Medicinal Chemistry • Library Development • SAR Studies • In Silico Screening • Chemical Synthesis In Vitro Studies • Drug Affinity and Selectivity • Cell Disease Models • MOA • Lead Candidate Refinement In Vivo Studies • Animal models of Disease States • Behavioural Studies • Functional Imaging • Ex-Vivo Studies Clinical Trials and Therapeutics
  • 14. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Target Selection • Target selection in drug discovery is defined as the decision to focus on finding an agent with a particular biological action that is anticipated to have therapeutic utility — is influenced by a complex balance of scientific, medical and strategic considerations. • Target identification: to identify molecular targets that are involved in disease progression. • Target validation: to prove that manipulating the molecular target can provide therapeutic benefit for patients.
  • 15. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Target Selection Biochemical Classes of Drug Targets  G-protein coupled receptors - 45%  enzymes - 28%  hormones and factors - 11%  ion channels - 5%  nuclear receptors - 2% Techniques for Target Identification
  • 16. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Cellular & Genetic Targets: Involves the identification of the function of a potential therapeutic drug target and its role in the disease process. For small-molecule drugs, this step in the process involves identification of the target receptors or enzymes whereas for some biologic approaches the focus is at the gene or transcription level. Drugs usually act on either cellular or genetic chemicals in the body, known as targets, which are believed to be associated with disease.
  • 17. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Cellular & Genetic Targets: Scientists use a variety of techniques to identify and isolate individual targets to learn more about their functions and how they influence disease. Compounds are then identified that have various interactions with the drug targets that might be helpful in treatment of a specific disease.
  • 18. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Genomics: The study of genes and their function. Genomics aims to understand the structure of the genome, including the mapping genes and sequencing the DNA. Seeks to exploit the findings from the sequencing of the human and other genomes to find new drug targets. Human Genome consists of a sequence of around 3 billion nucleotides (the A C G T bases) which in turn probably encode 35,000 – 50,000 genes.
  • 19. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Genomics: Drew’s estimates that the number of genes implicated in disease, both those due to defects in single genes and those arising from combinations of genes, is about 1,000 Based on 5 or 10 linked proteins per gene, he proposes that the number of potential drug targets may lie between 5,000 and 10,000. Single Nucleotide Polymorphism (SNP) libraries: are used to compare the genomes from both healthy and sick people and to identify where their genomes vary.
  • 20. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Proteomics: It is the study of the proteome, the complete set of proteins produced by a species, using the technologies of large – scale protein separation and identification. It is becoming increasingly evident that the complexity of biological systems lies at the level of the proteins, and that genomics alone will not suffice to understand these systems. It is also at the protein level that disease processes become manifest, and at which most (91%) drugs act. Therefore, the analysis of proteins (including protein-protein, protein- nucleic acid, and protein ligand interactions) will be utmost importance to target discovery.
  • 21. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Proteomics: Proteomics is the systematic high-throughput separation and characterization of proteins within biological systems. Target identification with proteomics is performed by comparing the protein expression levels in normal and diseased tissues. 2D PAGE is used to separate the proteins, which are subsequently identified and fully characterized with LC- MS/MS.
  • 22. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Bioinformatics: Bioinformatics is a branch of molecular biology that involves extensive analysis of biological data using computers, for the purpose of enhancing biological research. It plays a key role in various stages of the drug discovery process including  target identification  computer screening of chemical compounds and  pharmacogenomics
  • 23. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Cellular & Genetic Targets Genomics Proteomics Bioinformatics Bioinformatics: Bioinformatics methods are used to transform the raw sequence into meaningful information (eg. genes and their encoded proteins) and to compare whole genomes (disease vs. not). Can compare the entire genome of pathogenic and non- pathogenic strains of a microbe and identify genes/proteins associated with pathogenism Using gene expression micro arrays and gene chip technologies, a single device can be used to evaluate and compare the expression of up to 20000 genes of healthy and diseased individuals at once
  • 24. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening Lead Discovery: • Identification of small molecule modulators of protein function • The process of transforming these into high- content lead series.
  • 25. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening Synthesis and Isolation: • Separation of mixture • Separation of impurities • In vitro chemical synthesis • Biosynthetic intermediate
  • 26. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening Combinatorial Chemistry: Rapid synthesis of or computer simulation of large no. of different but structurally related molecules • Search new leads • Optimization of target affinity & selectivity. • ADME properties • Reduce toxicity and eliminate side effects
  • 27. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening Assay Development • Used for measuring the activity of a drug. • Discriminate between compounds. • Evaluate: • Expressed protein targets. • Enzyme/ substrate interactions.
  • 28. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening High throughput screening: • Screening of drug target against selection of chemicals. • Identification of highly target specific compounds.
  • 29. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Synthesis and Isolation Combinatorial Chemistry Assay Development High Throughput Screening High throughput screening:
  • 30. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis Medicinal Chemistry: • It’s a discipline at the intersection of synthetic organic chemistry and parmacology. • Focuses on small organic molecules (and not on biologics and inorganic compounds) • Used in • Drug discovery (hits) • Lead optimization (hit to lead) • Process chemistry and development
  • 31. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis Library Development: • Collection of stored chemicals along with associated database. • Assists in High Throughput Screening • Helps in screening of drug target (hit) • Based on organic chemistry
  • 32. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis SAR Studies: • Helps identify pharmacophore • The pharmacophore is the precise section of the molecule that is responsible for biological activity • Enables to prepare more active compound • Allow elimination of excessive functionality
  • 33. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis SAR Studies: Morphine Molecule
  • 34. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis In silico screening: • Computer simulated screening of chemicals • Helps in finding structures that are most likely to bind to drug target. • Filter enormous Chemical space • Economic than HTS
  • 35. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Library Development SAR Studies In Silico Screening Chemical Synthesis Chemical Synthesis: • Involve production of lead compound in suitable quantity and quality to allow large scale animal and eventual, extensive human clinical trials • Optimization of chemical route for bulk industrial production. • Suitable drug formulation
  • 36. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Drug Affinity and Selectivity Cell Disease Models MOA Lead Candidate Refinement In Vitro Studies: • (In glass) studies using component of organism i.e. test tube experiments • Examples- • Cells derived from multicellular organisms • Subcellular components (Ribosomes, mitochondria) • Cellular/ subcellular extracts (wheat germ, reticulocyte extract) • Purified molecules (DNA,RNA)
  • 37. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Drug Affinity and Selectivity Cell Disease Models MOA Lead Candidate Refinement In Vitro Studies: Advantages: • Studies can be completed in short period of time. • Reduces risk in post clinical trials • permits an enormous level of simplification of the system • investigator can focus on a small number of components
  • 38. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Drug Affinity and Selectivity Cell Disease Models MOA Lead Candidate Refinement Drug affinity and selectivity • Drug affinity is the ability of drug to bind to its biological target (receptor, enzyme, transport system, etc.) • Selectivity- Drug should bind to specific receptor site on the cell (eg. Aspirin)
  • 39. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Drug Affinity and Selectivity Cell Disease Models MOA Lead Candidate Refinement • Isogenic human disease models- are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro • Stem cell disease models-Adult or embryonic stem cells carrying or induced to carry defective genes can be investigated in vitro to understand latent molecular mechanisms and disease characteristics Cell disease models
  • 40. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Drug Affinity and Selectivity Cell Disease Models MOA Lead Candidate Refinement • Optimizing chemical hits for clinical trial is commonly referred to as lead optimization • The refinement in structure is necessary in order to improve • Potency • Oral Availability • Selectivity • pharmacokinetic properties • safety (ADME properties) Lead Candidate refinement
  • 41. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Animal models of Disease States Behavioural Studies Functional Imaging Ex-Vivo Studies In vivo studies • Its experimentation using a whole, living organism. • Gives information about, • Metabolic profile • Toxicology • Drug interaction
  • 42. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Animal models of Disease States Behavioural Studies Functional Imaging Ex-Vivo Studies Animal models of disease states • Test conditions involving induced disease or injury similar to human conditions. • Must be equivalent in mechanism of cause. • Can predict human toxicity in 71% of the cases. • Eg. SCID mice-HIV NOD mice- Diabetes Danio rerio- Gene function
  • 43. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Animal models of Disease States Behavioural Studies Functional Imaging Ex-Vivo Studies Behavioural Studies • Tools to investigate behavioural results of drugs. • Used to observe depression and mental disorders. • However self esteem and suicidality are hard to induce. • Example: • Despair based- Forced swimming/ Tail suspension • Reward based • Anxiety Based
  • 44. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Animal models of Disease States Behavioural Studies Functional Imaging Ex-Vivo Studies Functional Imaging: • Method of detecting or measuring changes in metabolism, blood flow, regional chemical composition, and absorption. • Tracers or probes used. • Modalities Used- • MRI • CT-Scan
  • 45. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Animal models of Disease States Behavioural Studies Functional Imaging Ex-Vivo Studies Ex-Vivo Studies: • Experimentation on tissue in an artificial environment outside the organism with the minimum alteration of natural conditions. • Counters ethical issues. • Examples: • Measurement of tissue properties • Realistic models for surgery
  • 46. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Clinical trials: • Set of procedures in medical research and drug development to study the safety and efficacy of new drug. • Essential to get marketing approval from regulatory authorities. • May require upto 7 years.
  • 47. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase 0: • Recent designation, also known as human micro-dosing studies. • First in human trials, conducted to study exploratory investigational new drug. • Designed to to speed up the development of promising drugs. • Concerned with- • Preliminary data on the drug’s pharmacodynamics and pharmacokinetics • Efficacy of pre-clinical studies.
  • 48. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase I: • Clinical Pharmacologic Evaluation • First stage of testing in human subjects. • 20-50 Healthy Volunteers • Concerned With: – Human Toxicity. – Tolerated Dosage Range – Pharma-cology/dynamics
  • 49. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase I: Types of Phase-I Trials • SAD (Single Ascending Dose) • MAD (Multiple Ascending Dose) • Food effect
  • 50. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase II: • Controlled Clinical Evaluation. • 50-300 Patients • Controlled Single Blind Technique • Concerned With: – Safety – Efficacy – Drug Toxicity – Drug Interaction
  • 51. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase III: • Extended Clinical Trials. • Most expensive & time consuming. • 250-1000 Patients. • Controlled Double Blind Technique. • Concerned With: – Safety, Efficacy – Comparison with other Drugs – Package Insert
  • 52. Target Selection Lead Discovery Medicinal Chemistry In Vitro Studies In Vivo Studies Clinical Trials Phase-I Phase-II Phase-III Phase-IV Phase IV: • Post Marketing Surveillance. • Designed to detect any rare or long-term adverse effects. • Adverse Drug Reaction Monitoring. • Pharmacovigilance.
  • 53. 10,000 COMPOUNDS 250 COMPOUNDS 5 COMPOUNDS 1 FDA APPROVED DRUG ~6.5 YEARS ~7 YEARS ~1.5 YEARS DRUG DISCOVERY PRECLINICAL CLINICAL TRIALS FDA REVIEW Drug Discovery & Development-Timeline
  • 54. Gene Therapy • Technique for correcting defective genes. • It is the process of inserting genes into cells to treat diseases. • Gene therapy is used to correct a deficient phenotype.
  • 55. Gene Therapy-Approaches Germline Gene Therapy  Sperm or eggs, are modified by the introduction of functional genes, which are integrated into their genomes.  Change would be heritable and would be passed on to later generations. Somatic Gene Therapy  The therapeutic genes are transferred Into the somatic cells of a patient.  Change will not be inherited by the patient's offspring or later generations.
  • 56. Gene Therapy- Types Ex Vivo Gene Therapy  Transfer of therapeutic genes in cultured cells which are then reintroduced into patient. Eg: Therapy for ADA Deficiency In Vivo Gene Therapy  The direct delivery of genes into the cells of a particular tissue is referred to as in vivo gene therapy. Eg: Therapy for Cystic fibrosis
  • 57. Gene Therapy- Vectors • Viruses Retroviruses Adenoviruses Adeno-associated viruses Herpes Simplex viruses • Pure DNA Constructs • Lipoplexes • DNA Molecular Conjugates • Human Artificial Chromosome
  • 58. Gene Therapy- Limitations • Short lived nature of gene therapy • Immune response • Problems with viral vectors • Multigene disorders
  • 59. Recent Developments • Nanotechnology + gene therapy yielded treatment to torpedo cancer • Results of world's first gene therapy for inherited blindness show sight improvement • New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma • Dual Gene Therapy Suppresses Lung Cancer in Preclinical Test
  • 60. Orphan Drugs: • An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease. • National Organization for Rare Disorders • European Organization for Rare Diseases
  • 61. Advantages: • Tax incentives. • Enhanced patent protection and marketing rights. • Clinical research financial subsidization. • Rise in research and developmen. • Crown Corporation.
  • 62. Orphan Drugs Act: • 4th January 1983 • 6000 Orphan Diseases • Unprofitable Drug Development • Affecting < 2,00,000 Persons • Orphan Drug Status to 1,090 Drugs • 1985 Amendment- Marketing Exclusivity Tourette Syndrome An Orphan Disease
  • 63. FDA Orphan Drug Approvals: 43 19 17 19 2 % Share Big Pharma Small Biopharma Established Biopharma Small & Medium Pharma
  • 64. Rare Diseases & Orphan Drugs: Sr. Disease Cause Orphan Drug 1. Gaucher’s Disease Glucocerbrosidase Enzyme Miglustat 2. Fabry’s Disease Galactosidase Enyme Galsidase β 3. Mucopolysaccharidosis Lysosomal Enzyme Laronidase 4. Tourette’s Syndrome Motor Tics Lamotrizine 5. Crohn’s Syndrome Unknown Infliximab 6. Wilson Disease Copper Deposition Trientine 7. SCID Adenosine Deaminase Enzyme Pegadimase